Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial

PLoS One. 2016 Mar 25;11(3):e0151637. doi: 10.1371/journal.pone.0151637. eCollection 2016.

Abstract

HIV-seropositive patients show high incidence of coronary heart disease and oxidative stress has been described as relevant key in atherosclerosis development. The aim of this study was to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients. We performed a randomized parallel controlled clinical trial in The Instituto Mexicano del Seguro Social, a public health hospital. 70 HIV-seropositive patients aged 20 to 55 on clinical score A1, A2, B1 or B2 receiving highly active antiretroviral therapy (HAART) were studied. They were randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline and at the end of the study, anthropometric measurements, lipid profile, glucose and stress oxidative levels [nitric oxide catabolites, lipoperoxides (malondialdehyde plus 4-hydroxialkenals), and glutathione] were evaluated. Principal HAART therapy was EFV/TDF/FTC (55%) and AZT/3TC/EFV (15%) without difference between groups. Treatment with omega 3 fatty acids as compared with placebo decreased triglycerides (-0.32 vs. 0.54 mmol/L; p = 0.04), but oxidative stress markers were not different between groups.

Trial registration: ClinicalTrials.gov NCT02041520.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Cholesterol / metabolism
  • Fatty Acids, Omega-3 / administration & dosage*
  • Female
  • Glutathione / metabolism
  • HIV / drug effects
  • HIV / pathogenicity
  • HIV Infections / diet therapy*
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Seropositivity / drug therapy
  • HIV Seropositivity / virology
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide / metabolism
  • Oxidative Stress / drug effects*
  • Viral Load / drug effects

Substances

  • Fatty Acids, Omega-3
  • Nitric Oxide
  • Cholesterol
  • Glutathione

Associated data

  • ClinicalTrials.gov/NCT02041520

Grant support

This research was funded by Instituto Mexicano del Seguro Social grant number FIS/IMSS/PROT/PRIO/12/019.